Compare Illinois Tool Works Inc. (ITW) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Illinois Tool Works Inc. trades at $263.78 (market cap $74.38B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Illinois Tool Works Inc. is far larger — about 4.4× Zimmer Biomet Holdings Inc's market cap, and Illinois Tool Works Inc. pays the higher dividend (2.63%). Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 67 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| ITW | ZBH | |
|---|---|---|
Market Cap | $74.38B | $16.95B |
Volume | 1,125,477 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $299.60 | $103.98 |
52-Week Low | $241.07 | $79.58 |
Typical Hold Time | 67 Days | 89 Days |
Enterprise Value | $83.23B | $24.02B |
Dividend Yield | 2.63% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $264.13, up 1.14% today, with a bearish technical signal but strong fundamentals including a 19.39% net income margin and three consecutive quarterly EPS beats. The stock is supported by a $1.72 quarterly dividend and a consensus price target of $276.86, though analyst ratings are mixed with 21.43% buy, 46.43% hold, and 32.14% sell. Recent news highlights its Dividend King status and institutional buying interest.
The outlook balances robust profitability and dividend reliability against technical weakness and modest revenue growth. Upside potential exists if earnings momentum continues, but risks include high valuation multiples and sector-specific headwinds. The stock presents a hold case for income-focused investors awaiting clearer technical improvement.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
